Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
Waugh, Norman, Cummins, E. (Ewen), Shyangdan, Deepson S., Court, Rachel A. and Mohiuddin, Syed (2012) Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. Manchester: National Institute for Health and Clinical Excellence (NICE). (NICE technology appraisal guidance).
WRAP_Waugh_Exenatide_prolonged_release.pdf - Published Version
Download (287Kb) | Preview
Official URL: http://www.nice.org.uk/ta248
Prolonged-release exenatide in triple therapy regimens (that is, in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as a treatment option for people with type 2 diabetes as described in 'Type 2 diabetes: the management of type 2 diabetes (NICE clinical guideline 87); that is, when control of blood glucose remains or becomes inadequate (HbA1c ≥ 7.5% [59 mmol/mol] or other higher level agreed with the individual), and the person has: a body mass index (BMI) ≥ 35 kg/m2 in those of European family origin (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight or a BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.
|Subjects:||R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences|
|Library of Congress Subject Headings (LCSH):||Non-insulin-dependent diabetes -- Treatment|
|Series Name:||NICE technology appraisal guidance|
|Publisher:||National Institute for Health and Clinical Excellence (NICE)|
|Place of Publication:||Manchester|
|Number of Pages:||55|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)